Cross-Sectional Observational Study About Prevalence of Metabolic Syndrome and Osteoporosis in Prostate Cancer Treated With Androgen Deprivation Therapy and Their Impact on Quality of Life (SIMBOSPROST): GICOR Group

García, J.; Ots, P.M. Samper; Kavadoy, Y. Ríos; Paniagua, M.L. Couselo; Iturre, E. Villafranca; Liñán, M. Rodríguez; Casas, Ana; Soria, Rodrigo; Martínez, B. Ludeña; Torrecilla, J. López

doi:10.1016/j.ijrobp.2013.06.934

International Journal of Radiation Oncology*Biology*Physics

2013

DOI: 10.1016/j.ijrobp.2013.06.934

|View full text |Cite

Cross-Sectional Observational Study About Prevalence of Metabolic Syndrome and Osteoporosis in Prostate Cancer Treated With Androgen Deprivation Therapy and Their Impact on Quality of Life (SIMBOSPROST): GICOR Group

J. García

P.M. Samper Ots

Y. Ríos Kavadoy

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

2022

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meta-analyses indicate that men receiving ADT are at a 75% increased risk of developing metabolic syndrome 3 . Incidence of metabolic syndrome ranges from 36% to 50% for patients receiving ADT over 12 to18 months 4,5 and is most pronounced when ADT is continuous rather than intermittent 4–6 . Reduction in testosterone from ADT also is associated with decreased libido, erectile dysfunction, hot flashes, nocturia, cognitive changes, fatigue, depression, and decreased quality of life 7 …”

mentioning

confidence: 99%

Androgen Deprivation and Sleep Disturbance

et al. 2022

View full text Add to dashboard Cite

BackgroundMen receiving androgen deprivation therapy (ADT) for prostate cancer (PC) are at risk for cardiovascular comorbidities and cognitive changes. Interventional research involves in-person assessment of physical fitness/activity and cognitive function, which has been negatively affected by the COVID-19 pandemic. Androgen deprivation therapy–related hot flashes and nocturia increase risk for insomnia. Insomnia is associated with fatigue and may exacerbate ADT-related cognitive changes.ObjectivesThe purpose of this mixed-methods pilot was to (1) determine feasibility/acceptability of remotely assessing physical fitness/activity, cognitive function, and sleep; (2) deliver telehealth cognitive behavioral training for insomnia (teleCBT-I) to improve sleep; and (3) garner qualitative feedback to refine remote procedures and teleCBT-I content.MethodsFifteen men with PC receiving ADT completed a 4-week teleCBT-I intervention. Videoconferencing was used to complete study assessments and deliver the weekly teleCBT-I intervention.ResultsSelf-report of sleep quality improved (P < .001) as did hot flash frequency (P = .04) and bother (P = .025). Minimal clinically important differences were detected for changes in insomnia severity and sleep quality. All sleep logs indicated improvement in sleep efficiency. Remote assessment of fitness/cognitive function was demonstrated for 100% of participants. Sufficient actigraph wear time allowed physical activity/sleep assessment for 80%. Sleep actigraphy did not demonstrate significant changes.ConclusionsRemote monitoring and teleCBT-I are feasible/acceptable to men with PC on ADT. Further research to confirm teleCBT-I efficacy is warranted in this population.Implications for PracticePreliminary efficacy for teleCBT-I interventions was demonstrated. Remote assessments of physical fitness/activity, sleep, and cognitive function may enhance clinical trial access for rural or economically disadvantaged PC survivors.

show abstract

mentioning

confidence: 99%

Androgen Deprivation and Sleep Disturbance

et al. 2022

View full text Add to dashboard Cite

show abstract

Mp57-16 Metabolic Syndrome in Patients With Prostate Cancer Undergoing Intermittent Androgen-Deprivation Therapy

Rezaei¹,

Ghoreifi²,

Rezaei³

et al. 2017

Journal of Urology

View full text Add to dashboard Cite

Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications

Tzortzis

Samarinas

Zachos

et al. 2017

View full text Add to dashboard Cite

Prostate cancer is the most common cancer among men and androgen deprivation therapy (ADT) is the most effective treatment for this disease. The cornerstone of the treatment of prostate cancer is inhibition of testosterone production which interrupts testosterone-induced growth of the prostate tumor. The dramatic decrease in testosterone levels, however, has several undesirable effects on the metabolic profile and bone metabolism and can also lead to fatigue, loss of libido, gynecomastia, and anemia, provoke vasomotor flushing, and generally affect the quality of life. Due to the long-term survival rates of patients with prostate cancer, treatmentrelated adverse effects are highly relevant and thus, in each clinical setting, the benefits of ADT must be weighed against treatment-related adverse effects. The current review focuses on the more recently described metabolic complications of androgen deprivation therapy, including obesity, diabetes, lipid alterations, metabolic syndrome, and cardiovascular disease. In addition, it provides practical management recommendations drawn from the available guidelines issued

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Cross-Sectional Observational Study About Prevalence of Metabolic Syndrome and Osteoporosis in Prostate Cancer Treated With Androgen Deprivation Therapy and Their Impact on Quality of Life (SIMBOSPROST): GICOR Group

Cited by 3 publications

References 0 publications

Androgen Deprivation and Sleep Disturbance

Androgen Deprivation and Sleep Disturbance

Mp57-16 Metabolic Syndrome in Patients With Prostate Cancer Undergoing Intermittent Androgen-Deprivation Therapy

Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications

Contact Info

Product

Resources

About